C-Reactive Protein As a Marker of Melanoma Progression
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Purpose: To investigate the association between blood levels of C-reactive protein (CRP) in patients with melanoma and overall survival (OS), melanoma-specific survival (MSS), and disease-free survival. Patients and Methods: Two independent sets of plasma samples from a total of 1,144 patients with melanoma (587 initial and 557 confirmatory) were available for CRP determination. Kaplan-Meier method and Cox regression were used to evaluate the relationship between CRP and clinical outcome. Among 115 patients who underwent sequential blood draws, we evaluated the relationship between change in disease status and change in CRP using nonparametric tests. Results: Elevated CRP level was associated with poorer OS and MSS in the initial, confirmatory, and combined data sets (combined data set: OS hazard ratio, 1.44 per unit increase of logarithmic CRP; 95% CI, 1.30 to 1.59; P < .001; MSS hazard ratio, 1.51 per unit increase of logarithmic CRP; 95% CI, 1.36 to 1.68; P < .001). These findings persisted after multivariable adjustment. As compared with CRP < 10 mg/L, CRP ≥ 10 mg/L conferred poorer OS in patients with any-stage, stage I/II, or stage III/IV disease and poorer disease-free survival in those with stage I/II disease. In patients who underwent sequential evaluation of CRP, an association was identified between an increase in CRP and melanoma disease progression. Conclusion: CRP is an independent prognostic marker in patients with melanoma. CRP measurement should be considered for incorporation into prospective studies of outcome in patients with melanoma and clinical trials of systemic therapies for those with melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Statin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030
C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC) (2011) · BMJ · doi:10.1136/bmj.d548 · Cited by 642
Association of C-Reactive Protein With Cardiovascular Disease Mortality According to Diabetes Status
Kengne, A. P., Batty, G. D., Hamer, M., Stamatakis, E., & Czernichow, S. (2012) · Diabetes Care · doi:10.2337/dc11-1588 · Cited by 105 · cited 1×
“An elevated level of CRP is a risk factor for cardiovascular disease and death resulting from cardiovascular causes in both men and women.(7-14) Prior investigations have demonstrated an association between CRP level and colorectal or lung cancer, but prospective studies have provided inconsistent evidence for an etio…”
BackgroundGenetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease
Elliott, P. (2009) · JAMA · doi:10.1001/jama.2009.954 · Cited by 35
Cited by
McQuade, J. L., Daniel, C. R., Hess, K. R., Mak, C., Wang, D. Y., Rai, R. R., Park, J. J., Haydu, L. E., Spencer, C., Wongchenko, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30078-0 · Cited by 664
Self-citationTsukamoto, H., Fujieda, K., Miyashita, A., Fukushima, S., Ikeda, T., Kubo, Y., Senju, S., Ihn, H., Nishimura, Y., & Oshiumi, H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0118 · Cited by 305
“CRP, a signature of inflammation and direct target of IL-6 signaling (36), has been reported to be associated with the clinical outcomes in melanoma patients (37) as well as LDH (32).”
BackgroundC-Reactive Protein and Cancer—Diagnostic and Therapeutic Insights
Hart, P. C., Rajab, I. M., Alebraheem, M., & Potempa, L. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.595835 · Cited by 275
Valpione, S., Pasquali, S., Campana, L. G., Piccin, L., Mocellin, S., Pigozzo, J., & Chiarion-Sileni, V. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1467-x · Cited by 201
Fang, S., Sui, D., Wang, Y., Liu, H., Chiang, Y.-J., Ross, M. I., Gershenwald, J. E., Cormier, J. N., Royal, R. E., Lucci, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.1357 · Cited by 71
Self-citation
Metadata
- Authors
- Fang, S., Wang, Y., Sui, D., Liu, H., Ross, M. I., Gershenwald, J. E., Cormier, J. N., Royal, R. E., Lucci, A., Schacherer, C. W., Gardner, J. M., Reveille, J. D., Bassett, R. L., Wang, L.-E., Wei, Q., Amos, C. I., & Lee, J. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-04-20
- Volume
- 33
- Issue
- 12
- Pages
- 1389-1396
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2133942235
- Cited by
- 85
- References
- 6
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: C-Reactive Protein As a Marker of Melanoma Progression. https://app.cochat.ai/papers/10.1200/jco.2014.58.0209
- The paper
- Fang, S., Wang, Y., Sui, D., Liu, H., Ross, M. I., Gershenwald, J. E., Cormier, J. N., Royal, R. E., Lucci, A., Schacherer, C. W., Gardner, J. M., Reveille, J. D., Bassett, R. L., Wang, L.-E., Wei, Q., Amos, C. I., & Lee, J. E. (2015). C-Reactive Protein As a Marker of Melanoma Progression. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.58.0209
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.